Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 2/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1338582 | 0.90 | CHRNB4 (0.53) | NISCHCHRNB4CHRNA3RAB9ANPC1 | |
| SCHEMBL105809 | 0.87 | NPC1 (0.41) | NISCHNPC1SMN1; SMN2 | |
| SCHEMBL20410845 | 0.83 | NPC1 (0.39) | NISCHNPC1SMN1; SMN2 | |
| SCHEMBL10520530 | 0.80 | KCNH2 (0.38) | CHRNB4CHRNA3NPC1SMN1; SMN2 | |
| Carbimide SCHEMBL29055881 | 0.80 | NPC1 (0.37) | NISCHNPC1SMN1; SMN2 | |
| SCHEMBL27260114 | 0.80 | NISCH (0.46) | NISCHNPC1SMN1; SMN2 | |
| SCHEMBL23054974 | 0.79 | KCNH2 (0.37) | CHRNB4CHRNA3NPC1 | |
| SCHEMBL7745017 | 0.79 | MECP2 (0.46) | HPGDALDH1A1MAPTKMT2A | |
| SCHEMBL4751753 | 0.79 | CHRNB4 (0.47) | CHRNB4CHRNA3ALDH1A1HSD17B10 | |
| SCHEMBL29364765 | 0.79 | CHRNB4 (0.47) | CHRNB4CHRNA3RAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115108987-B | N-substituted indenoisoquinolinone derivative and preparation method thereof | 华侨大学 | 2023-05-26 | — | — | CN | claimed |
| CN-115108987-A | N-substituted indenoisoquinolinone derivative and preparation method thereof | 华侨大学 | 2022-09-27 | — | — | CN | claimed |
| CN-115108987-B | N-substituted indenoisoquinolinone derivative and preparation method thereof | 华侨大学 | 2023-05-26 | — | — | CN | disclosed |
| CN-115108987-A | N-substituted indenoisoquinolinone derivative and preparation method thereof | 华侨大学 | 2022-09-27 | — | — | CN | disclosed |
| US-9212118-B2 | Synthesis of intermediates for preparing anacetrapib and derivatives thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-12-15 | — | — | US | disclosed |
| US-20140135368-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | LEK PHARMACEUTICALS D.D. (SI) | 2014-05-15 | — | — | US | disclosed |
| US-8063205-B2 | Method for producing 2-oxazoline analogue or 1,3-oxazine analogue | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063205-B2 | Method for producing 2-oxazoline analogue or 1,3-oxazine analogue | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2011-11-22 | — | — | US | disclosed |
| US-8063205-B2 | Method for producing 2-oxazoline analogue or 1,3-oxazine analogue | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2011-11-22 | — | — | US | disclosed |
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITY (JP) | 2009-11-12 | — | — | US | disclosed |
| EP-1956012-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | National University Corporation Hokkaido University (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1956012-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | National University Corporation Hokkaido University (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-0313994-B1 | Cross-linked resins | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1994-01-12 | — | — | EP | disclosed |
| EP-0548930-A1 | Method of producing hot melt resin for prepreg | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-30 | — | — | EP | disclosed |
| EP-0470104-A1 | A PROCESS FOR MAKING 2-OXAZOLINES | Henkel Kommanditgesellschaft auf Aktien (DE) | 1992-02-12 | — | — | EP | disclosed |
| WO-1990013546-A1 | A PROCESS FOR MAKING 2-OXAZOLINES | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1990-11-15 | — | — | WO | disclosed |
| EP-0394849-A1 | Process for the preparation of 2-oxazolines | Henkel Kommanditgesellschaft auf Aktien (DE) | 1990-10-31 | — | — | EP | disclosed |
| US-4902760-A | Cross-linked resins | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-02-20 | — | — | US | disclosed |
| EP-0313994-A1 | Cross-linked resins | Takeda Chemical Industries, Ltd. (JP) | 1989-05-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140135368-A1 | SYNTHESIS OF INTERMEDIATES FOR PREPARING ANACETRAPIB AND DERIVATIVES THEREOF | CYP2B6, CYP4B1, CIAPIN1 | NISCH 388/4885CHRNB4 3341/4885CHRNA3 3411/4885 |
| US-20090281309-A1 | METHOD FOR PRODUCING 2-OXAZOLINE ANALOGUE OR 1,3-OXAZINE ANALOGUE | OXA1L, SULT1A1, DAO | NISCH 1334/4885CHRNB4 1955/4885CHRNA3 795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.